EU makes recommendations for seasonal flu vaccines

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Scyther5)
(Image: Getty/Scyther5)

Related tags: Ema, Influenza, European union

The EMA issues advice on the composition of season flu vaccines for the 2019/2020 season for manufacturers.

The European Medicines Agency (EMA) has issued the European Union’s official recommendation for developing influenza vaccines for the 2019/2020 season.

The EMA recommended the following strains for trivalent vaccines:

  • A/Brisbane/02/2018 (H1N1)pdm09-like virus
  • A/Kansas/14/2017 (H3N2)-like virus
  • B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage)

In addition, it noted that for quadrivalent vaccines with two influenza B viruses, a B/Phuket/3073/2013-like virus should be included.

The advice will see manufacturers begin developing vaccines for the autumn of this year, as it takes five to six months​ to prepare specific vaccines prior to each season.

The recommendations apply to manufacturers of both inactivated and live attenuated influenza vaccines. The EMA arrived at these particular virus strains in consultation with the WHO, which just launched its global influenza strategy for the next decade​.

The influenza virus continuously mutates, necessitating a new vaccine to combat the spread of the virus – new vaccines are developed twice annually for the northern and southern hemispheres.

Every year, there are an estimated one billion cases of the influenza virus and between 290,000-650,000 deaths related to the virus.

As a result, pharmaceutical innovations in the space are still high in demand, which led to BioNTech signing a collaboration agreement with Pfizer​ worth a potential $425m (€378m) to develop a mRNA-based vaccine.

Beyond this, the search for a ‘universal flu vaccine’ is still on-going, with multiple companies​ involved in the race to develop the first commercially available treatment.

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers

Follow us

Products

View more